| Shi, Wei |
Oxycodone, NCT06690307: Versus Sufentanil in Patient-controlled Intravenous Analgesia After Laparoscopic Hysterectomy |
|
|
| Recruiting | 4 | 64 | RoW | patient controlled intravenous analgesia(PCIA) | Affiliated Hospital of Nantong University | Laparoscopic Hysterectomy | 12/25 | 07/26 | | |
CAPSTONE-1, NCT03711305: Study of Carboplatin Plus Etoposide With or Without SHR-1316 in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC) |
|
|
| Active, not recruiting | 3 | 462 | RoW | SHR-1316, Carboplatin, Etoposide, Placebo | Jiangsu HengRui Medicine Co., Ltd. | Extensive-stage Small Cell Lung Cancer | 10/22 | 12/23 | | |
PYRAMID-1, NCT04447118 / 2020-000951-11: Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy |
|
|
| Active, not recruiting | 3 | 151 | Europe, US, RoW | Pyrotinib, Irene, Docetaxel, Docetaxel injection | Jiangsu HengRui Medicine Co., Ltd. | Non-squamous NSCLC, HER2 Exon 20 Mutation | 06/23 | 10/23 | | |
TQ05105-III-01, NCT06682169: Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host Disease |
|
|
| Recruiting | 3 | 182 | RoW | Rovadicitinib, Imatinib, Methotrexate, Mycophenolate mofetil, Rituximab | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Graft-versus-host Disease | 10/29 | 12/30 | | |
NCT05674539: Reduced Intensity Conditioning Regimens for Acute Myeloid Leukemia and Myelodysplastic Syndrome |
|
|
| Recruiting | 3 | 200 | RoW | Fludarabine and Busulfan, Fludara and Busulfex, Fludarabine and Melphalan, Busulfex and Fludara | Wuhan Union Hospital, China | Acute Myeloid Leukemia, Adult, Myelodysplastic Syndrome(MDS), Allogeneic Hematopoietic Stem Cell Transplantation | 01/25 | 06/25 | | |
NCT03085069: A Study to Evaluate SHR-1210 in Patients With Advanced or Metastatic NSCLC |
|
|
| Active, not recruiting | 2 | 146 | RoW | SHR-1210 | Jiangsu HengRui Medicine Co., Ltd. | Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Respiratory Tract Neoplasms Nec, Lung Disease, Respiratory Tract Disease, Neoplasm, Bronchial, Carcinoma, Bronchogenic | 08/20 | 08/23 | | |
| Recruiting | N/A | 50000 | RoW | | Shanghai University of Traditional Chinese Medicine, Wangjing Hospital, China Academy of Chinese Medical Sciences, Dongzhimen Hospital, Beijing, The First Affiliated Hospital of Guangzhou University of TCM, Guangdong Provincial Hospital of Traditional Chinese Medicine, Affiliated Hospital of Changchun University of Chinese Medicine, Gansu Provincial Hospital, Guangzhou Kingmed Diagnostics Co., Ltd., Shandong Provincial Hospital of Traditional Chinese Medicine, Yunnan Provincial Hospital of Traditional Chinese Medicine, Shenzhen Pingle Orthopedic Hospital, First People's Hospital of Nankang District, Ganzhou City | Osteoporosis | 10/26 | 10/28 | | |
| Zhou, Caicun |
Orient-12, NCT03629925: Sintilimab in Combination With Gemcitabine and Platinum-Based Chemotherapy as First-Line Therapy for Advanced or Metastatic Squamous NSCLC |
|
|
| Completed | 3 | 357 | RoW | Sintilimab, IBI308, Gemcitabine, Cisplatin, Placebo, Carboplatin | Innovent Biologics (Suzhou) Co. Ltd. | Squamous NSCLC | 03/20 | 09/21 | | |
|
|
|
|
|
| Completed | 3 | 805 | Europe, RoW | Tislelizumab, BGB-A317, Docetaxel | BeiGene | Non-small Cell Lung Cancer | 08/20 | 01/24 | | |
|
|
|
|
|
|
CameL-sq, NCT03668496: A Study of SHR-1210 in Combination With Carboplatin + Paclitaxel in Subjects With Squamous NSCLC |
|
|
| Active, not recruiting | 3 | 390 | RoW | SHR-1210, The placebo | Jiangsu HengRui Medicine Co., Ltd. | Lung Cancer Squamous Cell, Lung Cancer Stage IV, PD-1 Antibody, Chemotherapy Effect | 11/20 | 12/21 | | |
EVIDENCE, NCT02448797: Icotinib as Adjuvant Therapy Compared With Standard Chemotherapy in Stage II-IIIA NSCLC With EGFR-mutation |
|
|
| Active, not recruiting | 3 | 320 | RoW | Icotinib, Conmana, Chemotherapy, Navelbine, ALIMTA | Betta Pharmaceuticals Co., Ltd. | Non-small Cell Lung Cancer | 06/22 | 12/23 | | |
| Active, not recruiting | 3 | 482 | RoW | KN046, KN046 placebo | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Squamous Non-small-cell Lung Cancer | 08/22 | 08/23 | | |
NCT04619433: A Study to Evaluate SHR-1210 in Combination With Famitinib Plus Chemotherapy in Subjects With NSCLC. |
|
|
| Recruiting | 3 | 560 | RoW | Camrelizumab;Pemetrexed and Carboplatin; Famitinib;, SHR1210, Camrelizumab;Pemetrexed and Carboplatin;Placebo | Jiangsu HengRui Medicine Co., Ltd. | Non-squamous Non-small-cell Lung Cancer | 12/22 | 10/23 | | |
PYRAMID-1, NCT04447118 / 2020-000951-11: Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy |
|
|
| Active, not recruiting | 3 | 151 | Europe, US, RoW | Pyrotinib, Irene, Docetaxel, Docetaxel injection | Jiangsu HengRui Medicine Co., Ltd. | Non-squamous NSCLC, HER2 Exon 20 Mutation | 06/23 | 10/23 | | |
| Recruiting | 3 | 500 | RoW | Pemetrexed, Carboplatin, Paclitaxel, Sintilimab, Cisplatin, Nab paclitaxel, Placebo | Innovent Biologics (Suzhou) Co. Ltd. | Non-Small Cell Lung Cancer | 09/26 | 10/28 | | |
NCT05042375: A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer |
|
|
| Recruiting | 3 | 450 | RoW | camrelizumab + famitinib, pembrolizumab, camrelizumab | Jiangsu HengRui Medicine Co., Ltd. | Non-small Cell Lung Cancer | 12/23 | 12/25 | | |
SKB264-Ⅲ-12, NCT06448312: A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer |
|
|
| Recruiting | 3 | 406 | RoW | SKB264, Pembrolizumab | Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. | Non-Small Cell Lung Cancer | 11/26 | 11/26 | | |
| Active, not recruiting | 3 | 398 | RoW | AK112, Pembrolizumab | Akeso | Advanced Non-small-cell Lung Cancer | 06/24 | 06/25 | | |
TRUST-III, NCT06564324: A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients |
|
|
| Not yet recruiting | 3 | 138 | NA | Taletrectinib, Crizotinib | AnHeart Therapeutics Inc. | Non Small Cell Lung Cancer | 01/29 | 09/30 | | |
NCT06031558: Phase III Study of SY-5007, a RET Inhibitor, in Patients With Locally Advanced or Metastatic RET Fusion-positive NSCLC |
|
|
| Recruiting | 3 | 120 | RoW | SY-5007, SY-5007 tablets | Shouyao Holdings (Beijing) Co. LTD | Non-Small Cell Lung Cancer | 09/24 | 06/26 | | |
SKB264-Ⅲ-14, NCT06711900: A Study of SKB264 in Combination with Pembrolizumab Versus Chemotherapy in Combination with Pembrolizumab As First-Line Treatment for PD-L1 Negative Patients with Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer |
|
|
| Recruiting | 3 | 432 | RoW | SKB264, Pembrolizumab, pemetrexed, carboplatin or cisplatin | Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. | Non-Small Cell Lung Cancer | 12/26 | 12/28 | | |
NCT05673590: Utidelone Versus Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer |
|
|
| Recruiting | 3 | 612 | RoW | Utidelone Injection, Docetaxel Injection | Beijing Biostar Pharmaceuticals Co., Ltd. | Locally Advanced or Metastatic Non-Small Cell Lung Cancer | 06/25 | 12/25 | | |
NCT05668988: A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28) |
|
|
| Recruiting | 3 | 320 | Europe, Canada, US, RoW | DZD9008, Pemetrexed+carboplatin | Dizal Pharmaceuticals | Non-small Cell Lung Cancer | 02/26 | 10/27 | | |
NCT06080776: SH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB NSCLC With Sensitizing EGFR Mutations |
|
|
| Recruiting | 3 | 242 | RoW | SH-1028 tablets, Placebo SH-1028 tablets | Nanjing Sanhome Pharmaceutical, Co., Ltd. | Non-small Cell Lung Cancer | 02/28 | 02/31 | | |
DUBHE-L-304, NCT05487391: A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection. |
|
|
| Recruiting | 3 | 632 | RoW | QL1706 injection, Vinorelbine Tartrate, Paclitaxel, Cisplatin, Carboplatin, Pemetrexed, Placebo | Qilu Pharmaceutical Co., Ltd. | Carcinoma, Non-Small-Cell Lung | 08/27 | 05/29 | | |
NCT04750083: HX008 Plus Chemotherapy VS Pembrolizumab Plus Chemotherapy As the First-line Treatment in Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer |
|
|
| Recruiting | 2/3 | 700 | RoW | HX008, Pembrolizumab, pemetrexed, cisplatin/carboplatin | Taizhou Hanzhong biomedical co. LTD | Nonsquamous Non-small Cell Lung Cancer | 09/22 | 09/23 | | |
NCT05001724: KN046 Plus Lenvatinib in Subject With Advanced Non-Small Cell Lung Cancer in the Failure of Anti-PD-(L)1 Agent |
|
|
| Terminated | 2/3 | 16 | RoW | KN046, Lenvatinib, Docetaxel | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Advanced Non-small Cell Lung Cancer | 02/23 | 04/23 | | |
NCT03904823: A Study of Famitinib in Combination With HS-10296 in Patients With EGFR-mutant NSCLC |
|
|
| Recruiting | 2 | 58 | RoW | famitinib po, HS-10296 po | Jiangsu HengRui Medicine Co., Ltd. | EGFR-mutant Non-Small Cell Lung Cancer | 12/22 | 12/22 | | |
NCT05519865: A Study of Tucidinostat Combined With Tislelizumab as First-line Treatment in Advanced NSCLC |
|
|
| Active, not recruiting | 2 | 118 | RoW | Tucidinostat, Chidamide, CS055, Tislelizumab | Chipscreen Biosciences, Ltd. | Non Small Cell Lung Cancer | 10/24 | 10/24 | | |
| Recruiting | 2 | 66 | RoW | BL-B01D1, PD-1 monoclonal antibody | Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Extensive-stage Small-cell Lung Cancer | 06/26 | 06/26 | | |
NCT04211922: Alkotinib Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib |
|
|
| Terminated | 2 | 4 | RoW | Alkotinib Capsules, ZG0418 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | ALK-positive Non-small Cell Lung Cancer | 10/22 | 10/22 | | |
NCT06498986: A Study of BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer |
|
|
| Recruiting | 2 | 40 | RoW | BL-B01D1, Osimertinib Mesylate Tablets | Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Non-small Cell Lung Cancer | 08/26 | 08/26 | | |
NCT05168566: Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer |
|
|
| Recruiting | 2 | 99 | US, RoW | Sutetinib Maleate Capsule, Sutetinib | Teligene US | Non-small Cell Lung Cancer | 08/24 | 02/25 | | |
YH001, NCT05212922: A Study to Evaluate in Combination With Toripalimab in Subjects With Advanced NSCLC and HCC |
|
|
| Withdrawn | 2 | 80 | Europe, RoW | YH001 + Toripalimab | Eucure (Beijing) Biopharma Co., Ltd | HCC, NSCLC Stage IIIB, NSCLC Stage IV | 12/24 | 03/25 | | |
NCT06724263: A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors |
|
|
| Not yet recruiting | 2 | 120 | RoW | B1962, B1962 is a PD-L1/VEGF bispecific antibody fusion protein. | Tasly Biopharmaceuticals Co., Ltd., Shanghai East Hospital | Recurrent Platinum-resistant Epithelial Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Cervical Cancers, Small Cell Lung Cancer, Hepatocellular Carcinoma (HCC), Colorectal Cancer, Non-Squamous Non-Small Cell Lung Cancer | 08/26 | 08/26 | | |
NCT05880706: A Study of BL-B01D1 and BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer |
|
|
| Recruiting | 2 | 114 | RoW | BL-B01D1, Osimertinib Mesylate Tablets | Sichuan Baili Pharmaceutical Co., Ltd. | Non-small Cell Lung Cancer | 07/25 | 07/25 | | |
| Recruiting | 1/2 | 108 | RoW | AK112 | Akeso | Non-small Cell Lung Cancer | 05/23 | 05/24 | | |
NCT05329298: A Phase 1/2 Study of BPI-361175 in Subjects With Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 90 | RoW | BPI-361175 | Betta Pharmaceuticals Co., Ltd. | Non-small Cell Lung Cancer | 06/23 | 12/23 | | |
HB0025-C-01, NCT06758557: A Phase Ib/II Study to Evaluate the Safety and Efficacy of HB0025 Injection in Patients With Advanced Solid Tumor |
|
|
| Recruiting | 1/2 | 282 | RoW | HB0025, Pemetrexed, Paclitaxel, Carboplatin | Huabo Biopharm Co., Ltd. | Advanced NSCLC, Advanced Endometrial Cancer | 10/25 | 02/26 | | |
NCT06243354: Phase 1/2 Study of HYP-2090PTSA in Patients With Advanced Solid Tumors Harboring KRAS Mutation |
|
|
| Recruiting | 1/2 | 257 | RoW | Test product: HYP-2090PTSA | Sichuan Huiyu Pharmaceutical Co., Ltd | Safety, Tolerability, Efficacy | 12/25 | 12/25 | | |
NCT06306456: A Phase Ib/II Clinical Study of GH21 Capsules Combined With Osimertinib Mesylate Tablets in Patients With NSCLC |
|
|
| Recruiting | 1/2 | 94 | RoW | GH21, Tagrisso | Suzhou Genhouse Bio Co., Ltd. | Non-Small Cell Lung Cancer With EGFR Mutation | 12/25 | 12/26 | | |
NCT04993391: AP-L1898 Capsule in Patients With Non-small Cell Lung Cancer |
|
|
| Recruiting | 1/2 | 156 | RoW | JS111(AP-L1898 Capsules) | Suzhou Junjing BioSciences Co., Ltd. | Lung Cancer | 06/24 | 08/24 | | |
TRIGGERCD8, NCT06468358: A Study to Evaluate LB1410 in Combination With LB4330 in Patients With Advanced or Metastatic Solid Tumors |
|
|
| Recruiting | 1/2 | 194 | RoW | LB1410, LB4330 | L & L biopharma Co., Ltd., Shanghai China, Shanghai East Hospital | Solid Tumor | 12/26 | 12/27 | | |
NCT06385678: A Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation |
|
|
| Enrolling by invitation | 1/2 | 70 | RoW | HRS-4642, Adebrelimab, SHR-A1921, Pemetrexed Disodium for Injection、Cisplatin Injection、Carboplatin for Injection | Jiangsu HengRui Medicine Co., Ltd. | Advanced KRAS G12D Mutant Solid Tumors | 10/25 | 08/26 | | |
NCT06631989: A Study to Assess the Efficacy and Safety of WSD0922-FU in Patients with EGFRm+ Advanced Non-small Cell Lung Cancer |
|
|
| Recruiting | 1/2 | 100 | RoW | WSD0922-FU | Wayshine Biopharm, Inc. | EGFR Mutation Positive Advanced Non-Small Cell Lung Cancer | 06/26 | 12/26 | | |
| Recruiting | 1/2 | 171 | Europe, US, RoW | STX-241 | Pierre Fabre Medicament | Non-small Cell Lung Cancer (NSCLC) | 11/27 | 07/30 | | |
NCT06499350: A Study of FC084CSA in Combination of Tislelizumab in Patients With Advanced Malignant Solid Tumors |
|
|
| Not yet recruiting | 1/2 | 33 | RoW | FC084CSA+Tislelizumab combination (dose escalation), FC084CSA+BGB-A317 combination (dose escalation), RP2D of FC084CSA+Tislelizumab combination (dose expansion), RP2D of FC084CSA+BGB-A317 combination (dose expansion) | FindCure Biosciences (ZhongShan) Co., Ltd. | Advanced Malignant Solid Tumors | 02/26 | 09/26 | | |
NCT06737731: A Phase I/II Clinical Study of SHR-1681 for Injection in Patients With Advanced Solid Tumors |
|
|
| Not yet recruiting | 1/2 | 300 | RoW | SHR-1681 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Malignant Solid Tumors | 11/26 | 07/27 | | |
NCT05278364: Phase I/II Study of SY-5007, a RET Inhibitor, in Patients With RET-altered Advanced Solid Tumor |
|
|
| Recruiting | 1/2 | 184 | RoW | SY-5007, SY-5007 Capsule | Shouyao Holdings (Beijing) Co. LTD | Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, Solid Tumor | 01/25 | 02/25 | | |
NCT05223231: Evaluation of LBL-019 Monotherapy or Combined With Anti-PD-1 Antibody in the Treatment of Advanced Malignant Tumors |
|
|
| Recruiting | 1/2 | 486 | RoW | LBL-019 Injection, LBL-019, anti-PD-1 antibody injection, anti-PD-1 antibody | Nanjing Leads Biolabs Co.,Ltd | Advanced Malignant Tumors | 03/25 | 10/25 | | |
Triumph-02, NCT05978401: Safety, Tolerability, and Efficacy of GLS-012 and GLS-010 in Patients With Advanced Non-Small Cell Lung Cancer |
|
|
| Not yet recruiting | 1/2 | 152 | RoW | GLS-012+GLS-010, LAG3, PD-1, GLS-012+GLS-010+pemetrexed+carboplatin, chemotherapy, GLS-012+GLS-010+paclitaxel+carboplatin | Guangzhou Gloria Biosciences Co., Ltd. | Advanced Non-Small Cell Lung Cancer | 04/25 | 04/26 | | |
| Recruiting | 1/2 | 233 | RoW | AK112, AK104, Carboplatin, paclitaxel, pemetrexed, Docetaxel | Akeso | Advanced Non-small-cell Lung Cancer | 04/25 | 01/27 | | |
NCT05949619 / CTR20232085: A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer or Other Solid Tumors |
|
|
| Recruiting | 1/2 | 60 | RoW | BL-M02D1 | Sichuan Baili Pharmaceutical Co., Ltd. | Non-small Cell Lung Cancer | 08/25 | 08/25 | | |
NCT05949606: A Study of SI-B001+SI-B003± Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer |
|
|
| Recruiting | 1/2 | 160 | RoW | SI-B001, SI-B003 | Sichuan Baili Pharmaceutical Co., Ltd. | Non-small Cell Lung Cancer | 11/25 | 11/25 | | |
NCT05994131: IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC |
|
|
| Recruiting | 1/2 | 110 | RoW | IN10018, BI 853520, Furmonertinib | InxMed (Shanghai) Co., Ltd. | NSCLC | 07/26 | 07/26 | | |
NCT04085185: A Study Evaluating the Safety, Tolerability, and Initial Efficacy of IBI110 in Subjects With Advanced Malignant Tumors |
|
|
| Recruiting | 1a | 268 | RoW | IBI110, IBI110+ Sintilimab | Innovent Biologics (Suzhou) Co. Ltd. | Advanced Malignancies | 12/23 | 06/24 | | |
NCT03852823: Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced Tumours |
|
|
| Recruiting | 1 | 192 | RoW | SG001, Recombinant Human Anti-PD-1 Monoclonal Antibody | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Advanced Solid Tumours, Cervical Cancer, Malignant Mesothelioma, Lymphoma, Non-Small-Cell Lung Cancer | 09/22 | 03/23 | | |
NCT05058352: A Study of HS269 in Patients With Advanced Solid Tumors |
|
|
| Not yet recruiting | 1 | 36 | RoW | HS269 | Zhejiang Hisun Pharmaceutical Co. Ltd. | Advanced Solid Tumor | 10/22 | 04/23 | | |
| Recruiting | 1 | 150 | RoW | GQ1005 | GeneQuantum Healthcare (Suzhou) Co., Ltd. | HER2 Expressing or Mutated Advanced Malignant Solid Tumors | 12/24 | 07/25 | | |
NCT06231550: A Study of Axl Inhibitor FC084CSA in Patients With Advanced Malignant Solid Tumors |
|
|
| Active, not recruiting | 1 | 43 | RoW | FC084CSA tablets | FindCure Biosciences (ZhongShan) Co., Ltd. | Advanced Malignant Solid Tumors | 12/24 | 02/25 | | |
| Recruiting | 1 | 280 | RoW | TQB2868 Injection | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Advanced Malignant Tumor | 06/23 | 06/24 | | |
NCT06132828: Evaluate the Safety, Tolerability, Pharmacokinetics of DR30206 in Patients With Advanced or Metastatic Solid Tumors |
|
|
| Recruiting | 1 | 182 | RoW | DR30206, DR30206 for Injection | Zhejiang Doer Biologics Co., Ltd. | Solid Tumor | 03/26 | 07/26 | | |
NCT05650385: A Study of B1962, a PD-L1/VEGF Bispecific Antibody Fusion Protein, for Advanced Solid Tumors |
|
|
| Not yet recruiting | 1 | 68 | RoW | B1962 | Tasly Biopharmaceuticals Co., Ltd. | Neoplasms Malignant | 12/23 | 10/25 | | |
| Recruiting | 1 | 156 | US, RoW | CS5001 | CStone Pharmaceuticals | Advanced Solid Tumor, Advanced Lymphoma | 03/25 | 06/25 | | |
|
| Recruiting | 1 | 96 | US, RoW | GQ1001 | GeneQuantum Healthcare (Suzhou) Co., Ltd., Conjugate Light (Australia) Pty Ltd | HER2-positive Breast Cancer, HER2-positive Biliary Tract Cancer, HER2-Positive Salivary Gland Carcinomas, HER2-Positive Advanced Solid Tumor | 03/24 | 05/24 | | |
KN-8701, NCT04913285: A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors |
|
|
| Recruiting | 1 | 400 | Europe, US, RoW | KIN-2787, exarafenib, KIN-2787 and binimetinib, exarafenib and binimetinib | Pierre Fabre Medicament | Solid Tumor, Adult, Non-small Cell Lung Cancer, Melanoma | 12/24 | 12/25 | | |
| Recruiting | 1 | 250 | RoW | QLC1101 | Qilu Pharmaceutical Co., Ltd. | Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Solid Tumor | 05/26 | 04/27 | | |
NCT05533463: Phase I Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation |
|
|
| Recruiting | 1 | 108 | RoW | HRS-4642 | Jiangsu HengRui Medicine Co., Ltd. | Advanced KRAS G12D Mutant Solid Tumors | 04/24 | 12/24 | | |
NCT05306132: Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of ASKC202 |
|
|
| Recruiting | 1 | 150 | RoW | ASKC202 | Jiangsu Aosaikang Pharmaceutical Co., Ltd. | Advanced Solid Tumor | 05/24 | 05/25 | | |
NCT06298058: A Clinical Trial of SIBP-A13 Injection in the Treatment of Advanced Malignant Solid Tumor Patients. |
|
|
| Recruiting | 1 | 144 | RoW | SIBP-A13 formulation for injection, Her3-ADC | Shanghai Institute Of Biological Products, Shanghai Pulmonary Hospital, Shanghai, China | Advanced Solid Tumor | 04/26 | 06/26 | | |
NCT05370755: A Study of ICP-189 and ICP-189 in Combination With Anti-PD-1 Monoclonal Antibody in Patients With Advanced Solid Tumors |
|
|
| Not yet recruiting | 1 | 22 | RoW | ICP-189 | Beijing InnoCare Pharma Tech Co., Ltd. | Patients With Advanced Solid Tumors | 05/24 | 01/26 | | |
NCT06424665: A Study of FZ-AD005 in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 162 | RoW | FZ-AD005 | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Advanced Solid Tumor, SCLC(Small Cell Lung Cancer) or LCNEC (Large Cell Neuroendocrine Carcinoma) | 12/25 | 06/26 | | |
NCT06505824: A Study of BL-M14D1 in Patients With Locally Advanced or Metastatic Small Cell Lung Cancer, Neuroendocrine Tumors and Other Solid Tumors |
|
|
| Recruiting | 1 | 22 | RoW | BL-M14D1 | Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Small Cell Lung Cancer, Neuroendocrine Tumors | 08/26 | 08/26 | | |
NCT06612840: A Study of GNC-077 in Patients With Locally Advanced or Metastatic Non-small-cell Lung Cancer and Other Solid Tumors |
|
|
| Recruiting | 1 | 20 | RoW | GNC-077 | Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Non-small Cell Lung Cancer, Solid Tumor | 10/26 | 10/26 | | |
NCT05357651: A Study to Assess the Safety and Efficacy of LB1410 in Participants With Advanced Solid Tumor or Lymphoma（Keyplus-001） |
|
|
| Recruiting | 1 | 100 | RoW | LB1410 | L & L biopharma Co., Ltd., Shanghai China | Solid Tumor, Lymphoma | 12/24 | 03/25 | | |
NCT06349408: IBI3001 in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors |
|
|
| Recruiting | 1 | 250 | RoW | IBI3001 | Innovent Biologics (Suzhou) Co. Ltd. | Locally Advanced Solid Tumor | 12/26 | 12/27 | | |
NCT06006793: A Study of SY-5933 in Patients With Advanced Solid Tumors Harboring the KRAS p.G12C Mutation |
|
|
| Recruiting | 1 | 50 | RoW | SY-5933, SY-5933 tablet | Shouyao Holdings (Beijing) Co. LTD | Advanced Solid Tumor | 02/25 | 08/25 | | |
NCT05772455: A Study of XZB-0004 in Patients With Solid Tumors |
|
|
| Recruiting | 1 | 128 | RoW | XZB-0004 | Xuanzhu Biopharmaceutical Co., Ltd. | Advanced Solid Tumor, NSCLC | 06/25 | 02/27 | | |
NCT05501912: A Study of ABM-1310 in Patients With BRAF V600-Mutant Advanced Solid Tumors |
|
|
| Terminated | 1 | 20 | RoW | ABM-1310 | ABM Therapeutics Shanghai Company Limited | Advanced Solid Tumor, BRAF V600 Mutation | 06/24 | 06/24 | | |
NCT06050980: Phase I Study of HSK40118 in NSCLC Patients With EGFR Mutation |
|
|
| Recruiting | 1 | 220 | RoW | HSK40118 | Haisco Pharmaceutical Group Co., Ltd. | NSCLC | 08/25 | 06/27 | | |
NCT04360655: Bronchoscopic Microwave Intervention Treatment in Advanced Central NSCLC |
|
|
| Not yet recruiting | N/A | 50 | NA | bronchoscopic microwave intervention, Local treatment, anti-PD-1 / PD-L1 monoclonal antibody and chemotherapy, Systemic treatment | Shanghai Pulmonary Hospital, Shanghai, China | Effect Increased, Safety Issues | 04/22 | 05/23 | | |
NCT04137718: Multicenter Observational Study of Chinese Non-Small Cell Lung Cancer (NSCLC) Patients With Rare Driver Gene Mutation |
|
|
| Recruiting | N/A | 50000 | RoW | nonIntervention | Shanghai Pulmonary Hospital, Shanghai, China | Chinese, Non-Small Cell Lung Cancer | 10/22 | 10/24 | | |
NCT06586801: The Patient-Reported Outcomes in ALK Positive Advanced NSCLC in China |
|
|
| Not yet recruiting | N/A | 800 | NA | Patient-reported outcome | Shanghai East Hospital, Zhejiang Cancer Hospital, Henan Cancer Hospital | Non-small Cell Lung Cancer | 05/25 | 09/26 | | |
Brilliant, NCT05721950: A Study to Learn About Brigatinib Treatment Information Available in Chinese Participants With Non-Small-cell Lung Cancer (NSCLC) |
|
|
| Recruiting | N/A | 200 | RoW | Brigatinib, Alunbrig | Takeda | Non-small Cell Lung Cancer (NSCLC) | 03/25 | 12/29 | | |
| Kang, Xiaoyan |
NCT03085069: A Study to Evaluate SHR-1210 in Patients With Advanced or Metastatic NSCLC |
|
|
| Active, not recruiting | 2 | 146 | RoW | SHR-1210 | Jiangsu HengRui Medicine Co., Ltd. | Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Respiratory Tract Neoplasms Nec, Lung Disease, Respiratory Tract Disease, Neoplasm, Bronchial, Carcinoma, Bronchogenic | 08/20 | 08/23 | | |
NCT05823285: A Study Evaluates the Safety, Pharmacokinetics, Immunogenicity and Efficacy of QLS31903 in Advanced Solid Tumor Patients |
|
|
| Recruiting | 1 | 150 | RoW | QLS31903 | Qilu Pharmaceutical Co., Ltd. | Advanced Solid Tumors | 06/25 | 06/27 | | |
